rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    CDXS
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Stifel reiterates Codexis stock rating on pharma demand strength
      Nov 13Investing.comCDXS
      Codexis Inc (CDXS) (Q3 2026) Earnings Call Highlights: Revenue Surges 124% as ECO Synthesis ...

      Codexis Inc (CDXS) posted $19.3 million in Q3 2026 revenue, its fourth straight on-target quarter, while advancing enzymatic oligonucleotide manufacturing and extending its cash runway through 2028.

      Nov 13Yahoo FinanceCDXS
      What Codexis (CDXS) Said on Its Q3 Earnings Call
      Nov 13Yahoo FinanceCDXS
      Earnings call transcript: Codexis tops Q3 2026 estimates, shares jump after hours
      Nov 12Investing.comCDXS
      Codexis earnings beat, revenue topped estimates
      Nov 12Investing.comCDXS
      Codexis (CDXS) Reports Q3 Loss, Beats Revenue Estimates
      Nov 12Yahoo FinanceCDXS
      Codexis: Q3 Earnings Snapshot
      Nov 12Yahoo FinanceCDXS
      Codexis Reports Third Quarter 2026 Financial Results and Provides Business Update
      Nov 12Yahoo FinanceCDXS
      Codexis secures $60M term loan from Trinity Capital
      Nov 10Investing.comCDXSTRIN
      Codexis Enters into $60 Million Term Loan Facility with Trinity Capital
      Nov 10Yahoo FinanceCDXS
      Codexis presents enzymatic RNA manufacturing data at TIDES Europe
      Nov 9Investing.comCDXS
      Codexis Advances ECO Synthesis Toward Adoption Readiness with Quality at Scale and Expanded siRNA Manufacturing Capabilities
      Nov 9Yahoo FinanceCDXS
      Codexis to Report Third Quarter 2026 Financial Results on November 12
      Oct 29Yahoo FinanceCDXS
      Temporary Delays in siRNA Manufacturing Mask Codexis’ (CDXS) High-Option Value
      Oct 22Yahoo FinanceCDXS
      Codexis CFO Georgia Erbez sells $8,619 of common stock
      Oct 14Investing.comCDXS
      President and CEO Alison Moore sells $8,619 in Codexis stock
      Oct 14Investing.comCDXS
      Codexis partners with siRNA innovator on enzyme synthesis
      Sep 28Investing.comCDXS
      Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNA

      REDWOOD CITY, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced an agreement with a pioneering siRNA drug innovator to explore stereo-defined fragment synthesis using its ECO Synthesis® Manufacturing Platform. The agreement builds on advances presented at TIDES USA 2026, where for the first time, Codexis demonstrated full-length siRNA synthesis with precise cont

      Sep 28Yahoo FinanceCDXS
      Analysts Have Conflicting Sentiments on These Healthcare Companies: Codexis (CDXS) and VistaGen Therapeutics (VTGN)

      Detailed price information for Vistagen Therapeutics Inc (VTGN-Q) from The Globe and Mail including charting and trades.

      Sep 24The Globe and MailCDXSVTGN
      Codexis at Cantor conference: enzymatic RNA manufacturing gains ground
      Sep 10Investing.comCDXS
      Codexis to Participate in Cantor Global Healthcare Conference 2026

      REDWOOD CITY, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced the Company will attend the Cantor Global Healthcare Conference 2026, being held September 9-11, 2026, in New York, New York. Management will participate in a fireside chat on Thursday, September 10, 2026, at 9:45 am ET. A live webcast of the event will be available in the Investor Relatio

      Aug 27Yahoo FinanceCDXS

      This is the newest page. Registered accounts read further back.